BSW practices, including Whalebridge, have currently been advised not to prescribe Tirzepatide (Mounjaro) for weight loss purposes. The BSW Integrated Care Board has released a public position statement outlining evidence-based recommendations for managing overweight and obesity in adults. You can view the full guidance here:
https://bsw.icb.nhs.uk/information-for-patients-on-new-weight-loss-drug-tirzepatide/